tradingkey.logo

Denali Therapeutics Announces Key Anticipated Milestones And Priorities For 2026

ReutersJan 6, 2026 2:00 PM

- Denali Therapeutics Inc DNLI.O:

  • DENALI THERAPEUTICS ANNOUNCES KEY ANTICIPATED MILESTONES AND PRIORITIES FOR 2026 INCLUDING COMMERCIAL LAUNCH OF TIVIDENOFUSP ALFA FOR HUNTER SYNDROME

  • DENALI THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD ON DNL952, PHASE 1 STUDY TO PROCEED

  • DENALI THERAPEUTICS INC - PREPARES FOR FDA APPROVAL AND LAUNCH OF TIVIDENOFUSP ALFA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI